文献リスト

1) Klunk WE, Mathis CA. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol. 2008; 21: 683-7

2) Friedland RP, Kalaria R, Berridge M, et al. Neuroimaging of vessel amyloid in Alzheimer's disease. Ann N Y Acad Sci. 1997; 826: 242-7

3) Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002; 10: 24-35

4) Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006; 355: 2652-63

5) Bresjanac M, Smid LM, Vovko TD, et al. Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malono­nitrile labels prion plaques in vitro. J Neurosci. 2003; 23: 8029-33

6) Boxer AL, Rabinovici GD, Kepe V, et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology. 2007; 69: 283-90

7) Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55: 306-19

8) Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004; 12: 584-95

9) Kudo Y, Okamura N, Furumoto S, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med. 2007; 48: 553-61

10) Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008; 131: 1630-45

11) Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh com­pound-B binding to Lewy bodies. J Neurosci. 2007; 27: 10365-71

12) Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007; 62: 229-34

13) Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007; 64: 431-4

14) Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cogni­tive impairment from two community-based studies. Neurology. 2006; 66: 1837-44

15) Price JL, Morris JC. Tangles and plaques in non­demented aging and “preclinical" Alzheimer's disease. Ann Neurol. 1999; 45: 358-68

16) Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in “normal" aging: evidence for preclini­cal Alzheimer disease in cognitively normal indi­viduals. J Neuropathol Exp Neurol. 1998; 57: 1168-74

17) Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential ante­cedent marker of Alzheimer disease. Neurology. 2006; 67: 446-52

18) Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007; 130: 2837-44

19) Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008; 131: 665-80

20) Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008; 65: 1509-17

21) Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated {beta}-amyloid deposition in elderly subjects. Brain. 2008; 132(Pt 5): 1310-23

22) Reiman EM, Chen K, Liu X, et al. Fibrillar amy­loid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009; 106: 6820-5

23) Villemagne VL, Pike KE, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008; 46: 1688-97

24) Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007; 68: 1718-25

25) Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008; 29: 1456-65

26) Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009; 132: 1310-23

27) Lopresti BJ, Klunk WE, Mathis CA, et al. Simpli­fied quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005; 46: 1959-72

28) Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007; 68: 1603-6

29) Koivunen J, Pirttila T, Kemppainen N, et al. PET amyloid ligand [11C]PIB uptake and cerebrospin­al fluid beta-amyloid in mild cognitive impair­ment. Dement Geriatr Cogn Disord. 2008; 26: 378-83

30) Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005; 25: 1528-47

31) Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and fronto­temporal lobar degeneration. Neurology. 2007; 68: 1205-12

32) Ng S, Villemagne VL, Berlangieri S, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med. 2007; 48: 547-52

33) Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007; 68: 501-8

34) Leinonen V, Alafuzoff I, Aalto S, et al. Assess­ment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008; 65: 1304-9

35) Ikonomovic MD AE, Hamilton RL, Mathis CA, et al. β-amyloid plaques in a PiB-PET negative subject: Implications for sensitivity of amyloid imaging in vivo. Alzheimer's & Dementia. 2009; 5: P029

36) Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005; 25: 10598-606

37) Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239-59

38) Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007; 27: 6174-84

39) Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006; 129(Pt 11): 2805-7

40) Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006; 59: 512-9

41) Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychi­atry. 2009; 65: 927-34

42) Drzezga A, Grimmer T, Henriksen G, et al. Imag­ing of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2008; 39: 619-33

43) Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2008; 35: 100-6

44) Johansson A, Savitcheva I, Forsberg A, et al. [(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism Relat Disord. 2008; 14: 345-7

45) Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia. Neuro­image. 2008; 39: 1027-33

46) Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008; 71: 903-10

47) Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychi­atry. 2008; 79: 1331-8

48) Ng SY, Villemagne VL, Masters CL, et al. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch Neurol. 2007; 64: 1140-4

49) Kambe T, Motoi Y, Ishii K, et al. Carbon 11-label­ed Pittsburgh compound B accumulation in the occipital cortex in posterior cortical atrophy. J Neurol. 2009 Nov 14. PMID: 19915884

50) Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurol­ogy. 2005; 64: 1553-62

51) Nicoll JA, Wilkinson D, Holmes C, et al. Neuro­pathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003; 9: 448-52

52) Masliah E, Hansen L, Adame A, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005; 64: 129-31

53) Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol. 2007; 34: 809-22

54) Jack CR, Jr., Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impair­ment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009; 132: 1355-65

55) Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008; 7: 129-35

56) Talan J. Neuroimaging tracers for AD detection not yet ready for prime time, FDA Panel advises. Neurology Today. 2008; 8: 1-8

57) Ono M. Development of positron-emission tomo­graphy/single-photon emission computed tomo­graphy imaging probes for in vivo detection of beta-amyloid plaques in Alzheimer's brains. Chem Pharm Bull(Tokyo). 2009; 57: 1029-39

58) Higuchi M, Iwata N, Matsuba Y, et al. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci. 2005; 8: 527-33

59) Skoch J, Dunn A, Hyman BT, et al. Development of an optical approach for noninvasive imaging of Alzheimer's disease pathology. J Biomed Opt. 2005; 10: 11007

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp